As chemoimmunotherapy trials in resectable NSCLC further mature, it is likely that so too will the value of PD-L1 expression as a prognostic tool, further reinforcing the need to assess PD-L1 expression prior to treatment initiation. This evidence concerns the gene CD274 and non-small cell lung carcinoma.